{"id":"https://openalex.org/W2068770010","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-65","title":"Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.","display_name":"Abstract LB-65: Towards defining the genetic framework for clinical response to treatment with BYL719, a PI3Kalpha-specific inhibitor.","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2068770010","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-65","mag":"2068770010"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2013-lb-65","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-65","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-lb-65","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031165814","display_name":"Jordi Ahnert Rodon","orcid":"https://orcid.org/0000-0001-6467-3632","observed_orcids":["https://orcid.org/0000-0001-6467-3632","https://orcid.org/0000-0003-2234-5248"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Jordi Rodon","raw_affiliation_strings":["1Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain;","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087308492","display_name":"Dejan Juric","orcid":"https://orcid.org/0000-0003-2983-7704","observed_orcids":["https://orcid.org/0000-0003-2983-7704"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dejan Juric","raw_affiliation_strings":["2Massachusetts General Hospital Cancer Center, Boston, MA;","2Massachusetts General Hospital - Cancer Center, Boston, MA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Massachusetts General Hospital Cancer Center, Boston, MA;","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"2Massachusetts General Hospital - Cancer Center, Boston, MA,","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114045827","display_name":"Ana-Maria Gonzalez-Angulo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ana-Maria Gonzalez-Angulo","raw_affiliation_strings":["3M.D. Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3M.D. Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028472820","display_name":"Johanna C. Bendell","orcid":"https://orcid.org/0000-0001-9426-5891","observed_orcids":["https://orcid.org/0000-0001-9426-5891"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Johanna Bendell","raw_affiliation_strings":["4Sarah Cannon Research Institute, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Sarah Cannon Research Institute, Nashville, TN;","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039492614","display_name":"Jordan D. Berlin","orcid":"https://orcid.org/0000-0001-7571-2385","observed_orcids":["https://orcid.org/0000-0001-7571-2385"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":null,"type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordan Berlin","raw_affiliation_strings":["5Vanderbilt Cancer Center, Nashville, TN;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Vanderbilt Cancer Center, Nashville, TN;","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082619050","display_name":"Douglas Bootle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Douglas Bootle","raw_affiliation_strings":["6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028939197","display_name":"Kathlene Gravelin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kathlene Gravelin","raw_affiliation_strings":["7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044141815","display_name":"Alan Huang","orcid":"https://orcid.org/0000-0001-5501-0212","observed_orcids":["https://orcid.org/0000-0001-5501-0212"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Alan Huang","raw_affiliation_strings":["7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070180093","display_name":"Adnan Derti","orcid":"https://orcid.org/0000-0002-8453-2244","observed_orcids":["https://orcid.org/0000-0002-8453-2244"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Adnan Derti","raw_affiliation_strings":["7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090425458","display_name":"Joseph Leh\u00e1r","orcid":"https://orcid.org/0000-0001-7743-4366","observed_orcids":["https://orcid.org/0000-0001-7743-4366"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph Lehar","raw_affiliation_strings":["7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064860542","display_name":"Jens W\u00fcrthner","orcid":"https://orcid.org/0000-0003-4838-435X","observed_orcids":["https://orcid.org/0000-0003-4838-435X"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Jens Wu\u0308rthner","raw_affiliation_strings":["6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065761868","display_name":"Markus Boehm","orcid":"https://orcid.org/0000-0002-7025-3287","observed_orcids":["https://orcid.org/0000-0002-7025-3287"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Markus Boehm","raw_affiliation_strings":["6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039044023","display_name":"Eliezer M. Van Allen","orcid":"https://orcid.org/0000-0002-0201-4444","observed_orcids":["https://orcid.org/0000-0002-0201-4444"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eliezer van Allen","raw_affiliation_strings":["8Broad Institute, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Broad Institute, Cambridge, MA;","institution_ids":["https://openalex.org/I107606265"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068721624","display_name":"Nikhil Wagle","orcid":"https://orcid.org/0000-0003-3332-9438","observed_orcids":["https://orcid.org/0000-0003-3332-9438"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nikhil Wagle","raw_affiliation_strings":["8Broad Institute, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Broad Institute, Cambridge, MA;","institution_ids":["https://openalex.org/I107606265"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055048393","display_name":"Levi A. Garraway","orcid":"https://orcid.org/0000-0003-3739-0471","observed_orcids":["https://orcid.org/0000-0003-3739-0471"]},"institutions":[{"id":"https://openalex.org/I107606265","display_name":"Broad Institute","ror":"https://ror.org/05a0ya142","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I107606265"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Levi A. Garraway","raw_affiliation_strings":["8Broad Institute, Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Broad Institute, Cambridge, MA;","institution_ids":["https://openalex.org/I107606265"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079433880","display_name":"Roman Yelensky","orcid":"https://orcid.org/0000-0002-5356-0111","observed_orcids":["https://orcid.org/0000-0002-5356-0111"]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":null,"type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":[],"is_corresponding":false,"raw_author_name":"Roman Yelensky","raw_affiliation_strings":["9Foundation Medicine, Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Foundation Medicine, Inc., Cambridge, MA;","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113642947","display_name":"Philip J. Stephens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":null,"type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":[],"is_corresponding":false,"raw_author_name":"Philip J. Stephens","raw_affiliation_strings":["9Foundation Medicine, Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Foundation Medicine, Inc., Cambridge, MA;","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111578811","display_name":"Vincent A. Miller","orcid":"https://orcid.org/0000-0003-1667-3771","observed_orcids":["https://orcid.org/0000-0003-1667-3771"]},"institutions":[{"id":"https://openalex.org/I4392738181","display_name":"Foundation Medicine (United States)","ror":"https://ror.org/02ackr434","country_code":null,"type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4392738181"]}],"countries":[],"is_corresponding":false,"raw_author_name":"Vincent A. Miller","raw_affiliation_strings":["9Foundation Medicine, Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"9Foundation Medicine, Inc., Cambridge, MA;","institution_ids":["https://openalex.org/I4392738181"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017177386","display_name":"Robert Schlegel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Schlegel","raw_affiliation_strings":["7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Oncology Translational Medicine, NIBR Inc., Cambridge, MA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033930240","display_name":"Cornelia Quadt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Cornelia Quadt","raw_affiliation_strings":["6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Oncology Translational Medicine, Novartis Pharma AG, Basel, Switzerland;","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004300577","display_name":"Jose M Baselga","orcid":"https://orcid.org/0000-0003-1361-4063","observed_orcids":["https://orcid.org/0000-0003-1361-4063"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose\u0301 Baselga","raw_affiliation_strings":["10Memorial Sloan-Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10Memorial Sloan-Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"73","issue":"8_Supplement","first_page":"LB","last_page":"65"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9380000233650208,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.04780000075697899,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.004000000189989805,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpelisib","display_name":"alpelisib","score":0.8320000171661377},{"id":"https://openalex.org/keywords/pi3kalpha-inhibitor","display_name":"PI3K\u03b1 inhibitor","score":0.8029999732971191},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.7839999794960022},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.9729999899864197},{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.8809999823570251},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.7540000081062317},{"id":"https://openalex.org/keywords/kras-mutation","display_name":"KRAS mutation","score":0.9520000219345093},{"id":"https://openalex.org/keywords/apc-mutation","display_name":"APC mutation","score":0.777999997138977},{"id":"https://openalex.org/keywords/pten-mutation","display_name":"PTEN mutation","score":0.9620000123977661},{"id":"https://openalex.org/keywords/pi3k-signaling","display_name":"PI3K signaling","score":0.5699999928474426},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.4399999976158142},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.6850000023841858},{"id":"https://openalex.org/keywords/cancer-genomics","display_name":"cancer genomics","score":0.5059999823570251},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.6579999923706055},{"id":"https://openalex.org/keywords/luminal-breast-cancer","display_name":"luminal breast cancer","score":0.953000009059906},{"id":"https://openalex.org/keywords/pten-loss","display_name":"PTEN loss","score":0.3889999985694885}],"concepts":[{"id":"https://openalex.org/C2777609662","wikidata":"https://www.wikidata.org/wiki/Q416356","display_name":"PTEN","level":4,"score":0.7208206057548523},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6046253442764282},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5643149018287659},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5008699893951416},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.47208520770072937},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.457256942987442},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4108273983001709},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41078007221221924},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.40754708647727966},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.37992575764656067},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3733866214752197},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.23088300228118896},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.0966547429561615}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2013-lb-65","doi":"https://doi.org/10.1158/1538-7445.am2013-lb-65","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-lb-65","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.7900000214576721,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4255321854","https://openalex.org/W2074517075","https://openalex.org/W3146426108","https://openalex.org/W2884617011","https://openalex.org/W3044672584","https://openalex.org/W2087724775","https://openalex.org/W2167243939","https://openalex.org/W2989121736","https://openalex.org/W2892677547","https://openalex.org/W2557359331"],"abstract_inverted_index":{"Abstract":[0],"Defining":[1],"predictive":[2],"biomarkers":[3,365],"and":[4,49,90,185,225,229,286,306,321,341],"deriving":[5],"appropriate":[6],"patient":[7],"populations":[8],"for":[9,119,484,506],"treatment":[10,354,370,488],"are":[11],"key":[12],"areas":[13],"of":[14,20,54,57,68,108,155,196,264,289,330,351,362,384,412,497,502],"interest":[15],"in":[16,42,61,80,113,144,220,294,314,319,338,377,403,424],"the":[17,55,98,114,124,145,152,179,204,208,221,290,310,339,363,378,404,413,481,498,503],"clinical":[18,27,128,156,180,234,405,485],"development":[19],"phosphatidyl-inositol-3-kinase":[21],"(PI3K)":[22],"inhibitors,":[23],"but":[24],"currently":[25],"most":[26,311],"trials":[28],"do":[29],"not":[30],"pre-select":[31],"patients":[32,120,142,171],"using":[33,254],"defined":[34,237],"genetic":[35,153,284,364,414,482],"markers.":[36],"Pre-clinical":[37],"studies":[38],"indicated":[39],"previously":[40],"that":[41,275,287,360,366,394,410],"vitro":[43,81],"sensitivity":[44,79,157,332,368,417],"to":[45,121,138,149,158,252,270,316,369,398,421,487],"BYL719,":[46,490],"a":[47,66,117,194,255,262,347,491],"potent":[48],"selective":[50],"small":[51],"molecule":[52],"inhibitor":[53],"\u03b1-isoform":[56],"PI3K,":[58],"was":[59,82,101,116,183,292],"increased":[60],"cell":[62],"lines":[63],"derived":[64],"from":[65,141,169,353],"subset":[67],"indications,":[69],"such":[70],"as":[71,236,325],"HER2-positive":[72],"or":[73,88,94,163,203,248,296,418],"luminal":[74],"breast":[75],"cancer.":[76],"Moreover,":[77],"BYL719":[78,104,125,146,253,331,372],"positively":[83],"correlated":[84,232],"with":[85,103,172,218,233,267,346,355,371,489],"PIK3CA":[86,111],"mutation":[87],"amplification":[89],"HER2":[91],"amplification.":[92],"PTEN":[93,307,342],"BRAF":[95],"mutation,":[96],"on":[97,216,261],"other":[99],"hand,":[100],"associated":[102,345],"insensitivity.":[105],"Consequently,":[106],"presence":[107],"an":[109],"activating":[110],"alteration":[112],"tumor":[115,139,165,244,250,278,298],"pre-requisite":[118],"enroll":[122],"into":[123,178],"first-in-human":[126],"(FIM)":[127],"trial.":[129,181],"In":[130],"this":[131,401],"study,":[132],"we":[133,273],"applied":[134],"massive":[135,189,388],"parallel":[136,190,389],"sequencing":[137,191],"specimens":[140,166],"enrolled":[143],"FIM":[147],"trial":[148,406],"comprehensively":[150],"assess":[151],"determinants":[154,415],"BYL719.":[159,356],"Paraffin-embedded":[160],"formalin-fixed":[161],"archival":[162],"pre-treatment":[164,277],"were":[167,212,230,309,323,344],"obtained":[168],"44":[170],"advanced":[173],"solid":[174],"tumors":[175,386],"upon":[176,382],"enrolment":[177],"DNA":[182],"isolated":[184],"then":[186],"assayed":[187],"by":[188,214,238,387],"covering":[192],"either":[193],"panel":[195,263],"182":[197],"cancer-related":[198],"genes":[199,217,266,291,343],"at":[200,207,281],"Foundation":[201],"Medicine":[202],"whole":[205],"exome":[206],"Broad":[209],"Institute.":[210],"Mutations":[211],"identified":[213,324],"focusing":[215],"alterations":[219],"COSMIC":[222],"data":[223],"base":[224],"excluding":[226],"germline":[227],"variants":[228],"subsequently":[231],"benefit":[235,352],"stable":[239],"disease":[240],"\u2265":[241,246],"4":[242],"months,":[243],"shrinkage":[245],"20%":[247],"objective":[249],"response":[251,486],"two-tailed":[256],"Fisher's":[257],"exact":[258],"test.":[259],"Focusing":[260],"51":[265],"known":[268],"relevance":[269],"PI3K":[271],"signaling,":[272],"observed":[274],"all":[276],"samples":[279],"harbored":[280],"least":[282],"one":[283,295],"abnormality":[285],"each":[288],"altered":[293,313],"several":[297],"samples.":[299],"TP53":[300,320],"(59%),":[301],"APC":[302,340],"(25%),":[303],"KRAS":[304,322],"(23%)":[305],"(18%)":[308],"frequently":[312],"addition":[315],"PIK3CA.":[317],"Alterations":[318],"statistically":[326],"significant":[327],"negative":[328],"predictors":[329],"(p":[333],"<":[334],"0.05),":[335],"while":[336],"mutations":[337],"trend":[348],"towards":[349],"lack":[350],"Our":[357],"results":[358],"suggest":[359],"definition":[361],"govern":[367],"and\u2013most":[373],"likely\u2013other":[374],"PI3K\u03b1":[375],"inhibitors":[376],"clinic":[379],"is":[380,396],"possible":[381],"analysis":[383],"patient's":[385],"sequencing.":[390],"We":[391],"also":[392],"demonstrate":[393],"it":[395],"feasible":[397],"routinely":[399],"obtain":[400],"information":[402],"setting.":[407],"This":[408],"implies":[409],"exploration":[411],"driving":[416],"primary":[419],"resistance":[420],"targeted":[422],"agents":[423],"general":[425],"can":[426],"now":[427],"be":[428],"undertaken":[429],"clinically.":[430],"Citation":[431],"Format:":[432],"Jordi":[433],"Rodon,":[434],"Dejan":[435],"Juric,":[436],"Ana-Maria":[437],"Gonzalez-Angulo,":[438],"Johanna":[439],"Bendell,":[440],"Jordan":[441],"Berlin,":[442],"Douglas":[443],"Bootle,":[444],"Kathlene":[445],"Gravelin,":[446],"Alan":[447],"Huang,":[448],"Adnan":[449],"Derti,":[450],"Joseph":[451],"Lehar,":[452],"Jens":[453],"Wu\u0308rthner,":[454],"Markus":[455],"Boehm,":[456],"Eliezer":[457],"van":[458],"Allen,":[459],"Nikhil":[460],"Wagle,":[461],"Levi":[462],"A.":[463,471],"Garraway,":[464],"Roman":[465],"Yelensky,":[466],"Philip":[467],"J.":[468],"Stephens,":[469],"Vincent":[470],"Miller,":[472],"Robert":[473],"Schlegel,":[474],"Cornelia":[475],"Quadt,":[476],"Jose\u0301":[477],"Baselga.":[478],"Towards":[479],"defining":[480],"framework":[483],"PI3Kalpha-specific":[492],"inhibitor.":[493],"[abstract].":[494],"In:":[495],"Proceedings":[496],"104th":[499],"Annual":[500],"Meeting":[501],"American":[504],"Association":[505],"Cancer":[507,517],"Research;":[508],"2013":[509],"Apr":[510],"6-10;":[511],"Washington,":[512],"DC.":[513],"Philadelphia":[514],"(PA):":[515],"AACR;":[516],"Res":[518],"2013;73(8":[519],"Suppl):Abstract":[520],"nr":[521],"LB-65.":[522],"doi:10.1158/1538-7445.AM2013-LB-65":[523]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2025-10-10T00:00:00"}